Market Opportunity

Aperion believes that regenerative medicine is one of the markets with the highest growth potential within the medical device industry. The potential size of the tissue engineering market totals $74 billion according to industry research. Within that market, the potential expenditures for ACL autografts and allografts are estimated to total over $3 billion worldwide. These figures include both the cost of allografts and the direct surgical costs of the autograft harvesting and subsequent direct incremental rehabilitation and medication costs.

Over 400,000 ACL reconstruction surgeries are performed in the U.S. annually. Aperion believes that the consistent supply of high quality allografts does not sufficiently match the demand for knee ligament procedures. Furthermore, the demand is expected to be driven higher by the expanding aging and active population suffering from degenerative ailments. Over 300,000 ACL reconstruction surgeries are performed in Europe annually. The vast majority of such surgeries were performed using autografts. Throughout most of Europe, allografts are available on a very limited basis.

As for the markets applicable to Aperion’s earlier stage pipeline, the addressable U.S. and European markets for extracellular matrices, wound healing, bone replacement and heart valve replacement are $2.0 billion, $4.0 billion, $10.8 billion and $700 million, respectively.

©2009 Aperion Biologics Corporation. All rights reserved. Privacy policy. Access to and use of this Web site is subject to these Terms of Use.